BridgeBio Oncology Therapeutics, Inc (BBOT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BridgeBio Oncology Therapeutics, Inc (BBOT) is down 35.9% since the beginning of the year. At $8 per share, BBOT is trading 46.0% below its 52-week high of $15.

Based on dividend-adjusted daily data since Aug 12, 2025, BBOT's average daily return is +0.01%, while the average monthly return is -1.03%.

Historically, 45% of months were positive and 55% were negative. The best month was Sep 2025 with a return of +29.5%, while the worst month was Feb 2026 at -14.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, BBOT closed higher 47% of trading days. The best single day was Dec 5, 2025 with a return of +18.6%, while the worst single day was Aug 19, 2025 at -15.6%.

BridgeBio Oncology Therapeutics, Inc has an annualized alpha of -21.34%, beta of 1.28, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since August 13, 2025.

• This stock participated in 374.77% of S&P 500 Index downside but only 77.21% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the BridgeBio Oncology Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the BridgeBio Oncology Therapeutics, Inc was 44.21%, occurring on May 8, 2026. The portfolio has not yet recovered.

The current BridgeBio Oncology Therapeutics, Inc drawdown is 41.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of BridgeBio Oncology Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how BridgeBio Oncology Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.